Related references
Note: Only part of the references are listed.Five-year survival decreases over time in patients with BRCA-mutated ovarian cancer: a systemic review and meta-analysis
Chen Nahshon et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2022)
Combined PD-1/PD-L1 and tumor-infiltrating immune cells redefined a unique molecular subtype of high-grade serous ovarian carcinoma
Ping Liu et al.
BMC GENOMICS (2022)
Development and Validation of a Tumor Mutation Burden-Related Immune Prognostic Signature for Ovarian Cancers
Mengjing Cui et al.
FRONTIERS IN GENETICS (2022)
Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors
Razvan Cristescu et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma
Zhao Cheng et al.
CLINICAL CANCER RESEARCH (2022)
Delay in adjuvant chemotherapy administration for patients with FIGO stage I epithelial ovarian carcinoma is associated with worse survival; an analysis of the National Cancer Database
Dimitrios Nasioudis et al.
GYNECOLOGIC ONCOLOGY (2022)
Ovarian cancer mutational processes drive site-specific immune evasion
Ignacio Vazquez-Garcia et al.
NATURE (2022)
A comprehensive analysis of somatic alterations in Chinese ovarian cancer patients
Yingli Zhang et al.
SCIENTIFIC REPORTS (2021)
Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis
Chen Zhang et al.
FRONTIERS IN ONCOLOGY (2021)
Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)
Kathleen N. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study
Eric Pujade-Lauraine et al.
LANCET ONCOLOGY (2021)
The Frequency and Prognostic Significance of the Histologic Type in Early-stage Ovarian Carcinoma A Reclassification Study by the Spanish Group for Ovarian Cancer Research (GEICO)
Susanna Leskela et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2020)
Mismatch Repair Deficiency in Ovarian Carcinoma Frequency, Causes, and Consequences
Susanna Leskela et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2020)
Expression of the Immune Checkpoints LAG-3 and PD-L1 in High-grade Serous Ovarian Carcinoma: Relationship to Tumor-associated Lymphocytes and GermlineBRCAStatus
Rachel Whitehair et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2020)
PD-1/PD-L1 expression and tumor-infiltrating lymphocytes are prognostically favorable in advanced high-grade serous ovarian carcinoma
Laura Martin de la Fuente et al.
VIRCHOWS ARCHIV (2020)
Molecular Heterogeneity of Endometrioid Ovarian Carcinoma
Susanna Leskela et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2020)
PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Different Types of Tubo-Ovarian Carcinoma and Their Prognostic Value in High-grade Serous Carcinoma
Hao Chen et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2020)
Morphological and molecular heterogeneity of epithelial ovarian cancer: Therapeutic implications
Ignacio Romero et al.
EJC SUPPLEMENTS (2020)
BRCA Mutations, Homologous DNA Repair Deficiency, Tumor Mutational Burden, and Response to Immune Checkpoint Inhibition in Recurrent Ovarian Cancer
Ying L. Liu et al.
JCO PRECISION ONCOLOGY (2020)
Prognostic impact of tumor-infiltrating lymphocytes in high grade serous ovarian cancer: a systematic review and meta-analysis
Jiatao Hao et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)
Discovery of prognostic markers for early-stage high-grade serous ovarian cancer by MALDI-Imaging
H. Kulbe et al.
GEBURTSHILFE UND FRAUENHEILKUNDE (2020)
Tumor infiltrating lymphocytes and homologous recombination deficiency are independently associated with improved survival in ovarian carcinoma
Christopher B. Morse et al.
GYNECOLOGIC ONCOLOGY (2019)
The effect of adjuvant chemotherapy on survival in patients with FIGO stage I high-grade serous ovarian cancer
J. O. A. M. van Baal et al.
GYNECOLOGIC ONCOLOGY (2019)
Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers
Cecile Le Page et al.
BMC CANCER (2018)
Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics
Jaime Prat et al.
HUMAN PATHOLOGY (2018)
Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors
S. Y. Cindy Yang et al.
GENOME MEDICINE (2018)
Prognostic value of tumor PD-L1 expression combined with CD8+ tumor infiltrating lymphocytes in high grade serous ovarian cancer
Qiaohong Wang et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2017)
The prognostic value of tumor-infiltrating T lymphocytes in ovarian cancer
Jun Li et al.
ONCOTARGET (2017)
Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma
Silvia Darb-Esfahani et al.
ONCOTARGET (2016)
Morphological and Immunohistochemical Reevaluation of Tumors Initially Diagnosed as Ovarian Endometrioid Carcinoma With Emphasis on High-grade Tumors
Diana Lim et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2016)
Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status
Joanne Kotsopoulos et al.
GYNECOLOGIC ONCOLOGY (2016)
PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer
John R. Webb et al.
GYNECOLOGIC ONCOLOGY (2016)
An Immunohistochemical Algorithm for Ovarian Carcinoma Typing
Martin Kobel et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2016)
Germline Mutation in BRCA1 or BRCA2 and Ten-Year Survival for Women Diagnosed with Epithelial Ovarian Cancer
Francisco J. Candido-dos-Reis et al.
CLINICAL CANCER RESEARCH (2015)
Optimal treatment of early-stage ovarian cancer
F. Collinson et al.
ANNALS OF ONCOLOGY (2014)
Tumor-Infiltrating Lymphocytes Expressing the Tissue Resident Memory Marker CD103 Are Associated with Increased Survival in High-Grade Serous Ovarian Cancer
John R. Webb et al.
CLINICAL CANCER RESEARCH (2014)
The Ratios of CD8+ T Cells to CD4+ CD25+ FOXP3+ and FOXP3- T Cells Correlate with Poor Clinical Outcome in Human Serous Ovarian Cancer
Claudia C. Preston et al.
PLOS ONE (2013)
Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer
Kelly L. Bolton et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma
Robert A. Soslow et al.
MODERN PATHOLOGY (2012)
Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features
Jaime Prat
VIRCHOWS ARCHIV (2012)
Integrated genomic analyses of ovarian carcinoma
D. Bell et al.
NATURE (2011)
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
E Sato et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer
L Zhang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Share Paper
